Predicting Response to Atomoxetine and Methylphenidate

ID Number 03-0612

Principal Investigator(s)
Jeffrey Newcorn

Department(s) or Division(s)

Research Entity
Center of Excellence in ADHD and Related Disorders


The purpose of this study is three-fold. First, to compare the efficacy of four to five weeks of treatment with methylphenidate (Concerta™) and atomoxetine (Strattera™) on ADHD symptoms and associated functional impairment. Second, to evaluate differences in adverse effects and palatability between the two treatments. Third, to evaluate clinical and pharmacogenetic moderators of response to the two treatments.

Contact Information
Beth K. Krone, CRC
(212) 659-8833

Recruiting Patients: No